Neogen CorpNEOG

NasdaqHealthcareIn Vitro & In Vivo Diagnostic Substances
Price (close)
$13.66
Market cap
$3.0B
P/E
—
Revenue (TTM)
$870.4M
Net income
-$7.9M
Dividend yield
—
1-year total return
154.9%
Net margin
-0.9%
Revenue growth
-2.7%
Debt / equity
0.38x

What Neogen Corp does.

Neogen Corporation and its subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. We also have products to determine food quality and nutritional components. The majority of the test kits are consumables, single-use culture, immunoassay and nucleic acid detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. Our line of food safety services also includes advanced software systems that help testers objectively analyze, store and identify emerging issues from their results from multiple locations over extended periods.

Neogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, insect control products and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through veterinarians, retailers, livestock producers and animal health product distributors. Our line of drug detection products is sold worldwide for the detection of abused and therapeutic drugs in animals and animal products, and has expanded into the workplace testing and human forensic markets. In July 2025, the Company divested its global Cleaners and Disinfectants business. See Note 4. "Assets Held for Sale and Divestiture" to the consolidated financial statements for further discussion.

Revenue and profit, by fiscal year.

Fiscal year202120222023202420252026
Revenue$468.5M$527.2M$822.4M$924.2M$894.7M$870.4M
Net income$60.9M$48.3M-$22.9M-$9.4M-$1.1B-$7.9M
Free cash flow$54.4M$43.6M-$24.7M-$76.1M-$46.4M$31.9M

More on NEOG.

Figures from Neogen Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.